Connect Biopharma Holdings (CNTB) Cash from Financing Activities (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Cash from Financing Activities for 3 consecutive years, with $17.6 million the latest figure, recorded in Q1 2026.

• Quarterly Cash from Financing Activities rose 881000.0% year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.7 million (up 8071.62% YoY) and the FY2025 annual result came in at $1.1 million, up 381.5% from the prior year.
• Cash from Financing Activities climbed to $17.6 million in Q1 2026 per CNTB's latest filing, from $715000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for CNTB reached as high as $17.6 million in Q1 2026 and fell as low as $2000.0 in Q1 2025.
• A 3-year average of $2.7 million and a median of $161000.0 in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities surged 33.06% — and 2026, when it surged 881000.0%.
• Year by year, Cash from Financing Activities stood at $106000.0 in 2024, then surged by 574.53% to $715000.0 in 2025, then soared by 2364.62% to $17.6 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $17.6 million, $715000.0, and $215000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.